B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.